Investors & Media

Investor Relations

- 0.36
Day High
Day Low
4:00 PM ET on Nov 25, 2014
Stock price graph

TG Therapeutics, Inc.  is an innovative, clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of innovative and medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. Currently, the company is developing two advanced therapies targeting hematological malignancies. TGTX-1101 (ublituximab) is a novel, third generation monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes, currently in clinical development for patients with relapsed and refractory non-Hodgkin's lymphoma. TG Therapeutics is also developing TGR-1202, a highly specific, orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B‐cell lymphocytes. TG Therapeutics is headquartered in New York City.

View all »   RSSRecent Releases

Nov 25, 2014
TG Therapeutics, Inc. to Present at the 2014 Deutsche Bank BioFEST Conference

Nov 10, 2014
TG Therapeutics, Inc. Announces Third Quarter 2014 Financial Results and Business Update

View all »Events & Presentations

Dec 1, 2014 at 2:50 PM ET
2014 Deutsche Bank BioFEST